We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Overview of Non Tuberculosis Mycobacterial Lung Diseases

Chamila Priyangani Adikaram

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.73542>

Abstract

Nontuberculosis mycobacteria (NTM) are ubiquitous in nature and opportunistically infect different animals, including humans. Currently, NTM is emerging as an important cause of pulmonary infection among both immunocompromised and immunocompetent persons worldwide. The clinical relevance of pulmonary NTM varies among species while showing geographical heterogeneity in distribution as well as pathogenicity. The outcome of the respiratory NTM disease is a consequence of a complex interplay between microbial factors and host susceptibility. Furthermore, HIV infection, cystic fibrosis, cancer, underlying chronic lung disease and history of tuberculosis (TB) may be associated as risk factors for active nontuberculosis pulmonary diseases (NTMPD). The diagnosis of NTMPD requires the presence of symptoms, radiographic evidences, microscopic observations and definitive laboratory diagnostics. Lung infections resulted from a clinically significant NTM species should be treated with appropriate antimicrobial regimen.

Keywords: nontuberculosis mycobacteria, NTM, lung infections, NTM diagnosis, NTM infection

1. Introduction to genus *Mycobacterium*

The genus *Mycobacterium* was first proposed in 1896 by Lehmann and Neumann [1]. Currently, it contains about 160 species and it is likely that more will be discovered with recently developed more precise species identification techniques [2, 3]. Most species exist as free-living saprophytes and only minorities are successful as pathogens of higher vertebrates. The host-dependent mycobacteria are capable of reproducing *in vitro*. In contrast,

M. leprae and *M. lepraemurium* are uncultivable and require the intracellular milieu for survival and propagation [4].

The obligatory causative agents of the genus *Mycobacterium*, responsible for TB are classified into *Mycobacterium tuberculosis* complex (MTC). It comprises *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. microti* [5], *M. canettii* [6], *M. caprae* [7], *M. pinnipedii* [8], *M. mungi* [9], *M. orygis* [10] and *M. suricattae* [11] species. *M. tuberculosis*, *M. africanum*, *M. canettii* and *M. orygis* cause TB primarily in human [4, 10], whereas *M. bovis* [12], *M. microti* [13], *M. caprae* [7] *M. pinnipedii* [8], *M. mungi* [9] and *M. suricattae* [11] infect cattle, domestic animals, goats, seals, mongooses and meerkats, respectively, and animal tuberculosis can also be zoonotic [14, 15]. However, geographical variation of the MTC species distribution has been identified. As an example, *M. africanum* is a common cause of human pulmonary TB (39%) as much as *M. tuberculosis* (55%) in West Africa [16]. In Ghana, 3% of pulmonary TB cases are represented by *M. bovis*, while 20% are *M. africanum* and 73% are *M. tuberculosis* [17].

Other medically important mycobacteria such as *M. avium*, *M. intracellulare* complex, *M. kansasii*, *M. marinum*, *M. fortuitum*, *M. chelonae* complex, *M. abscessus* and *M. scrofulaceum* are known as nontuberculosis mycobacteria (NTM) species or atypical mycobacteria or mycobacteria other than tuberculosis (MOTT). They are responsible for diseases including lymphadenitis in children, chronic pulmonary diseases, skin and soft-tissue diseases and infections of the skeletal system [18].

NTM are ubiquitous in nature and are widely distributed in water, soil and animals. Among prevailing NTM species, only a few species have a clinical impact on humans as opportunistic pathogens [19]. *M. avium* complex (MAC), *M. abscessus*, *M. kansasii*, *M. fortuitum*, *M. chelonae*, *M. szulgai*, *M. triviale* and *M. scrofulaceum* are common NTM species that cause pulmonary diseases in human [20]. Additionally, *M. riyadhense* was recently proposed as a causative agent of pulmonary NTM disease [21]. However, NTM are increasingly recognized as a significant cause of chronic human pulmonary infections in both immunocompromised and immunocompetent patients [3].

In contrast to TB, diseases caused by NTM have varied clinical manifestations, triggering a wide spectrum of infections with generally low virulence than TB [20]. Patients with underlying structural lung diseases such as chronic obstructive pulmonary diseases, cystic fibrosis, bronchiectasis, history of TB and chronic aspiration are more vulnerable to develop NTM lung disease [22]. Additionally, working in mining industry and advanced age are risk factors for NTM lung diseases. However, there is no evidence on animal-to-human (zoonosis) or human-to-human transmission of NTM, and human diseases are generally acquired from environmental exposure [22].

2. NTM species significant to lung diseases

NTM are emerging worldwide as significant causes of chronic pulmonary infection, while became a challenge for both clinicians and researchers in the past two to three decades [23]. However, isolation and discover of new NTM species from pulmonary clinical specimens have become frequent in the last years especially with the development of species identification techniques such as sequencing of 16S ribosomal DNA (rDNA) [24].

The pathogenicities of the different NTM species vary widely and show geographical heterogeneity. Commonly, most NTMPD infections are caused by the MAC, *M. abscessus*, *M. kansasii* [25, 26], *M. fortuitum*, *M. chelonae* [26], *M. szulgai*, *M. gordonae*, *M. vaccae* and *M. smegmatis* [20, 27].

MAC organisms are common in many environmental sites, including water and soil, and in animals as well as colonize in natural water sources, indoor water systems, pools and hot tubs [28]. Previously, MAC, a slow growing NTM species has been composed of *M. avium* and *M. intracellulare* but, with advance in genetic identification of species, MAC encompasses at least 10 species, i.e. *M. avium*, *M. intracellulare*, *M. arosiense*, *M. bouchedurhonense*, *M. chimaera*, *M. colombiense*, *M. marseillense*, *M. timonense*, *M. vulneris* and *M. yongonense*, as well as 4 subspecies, i.e. *M. avium* subsp. *avium*, *M. avium* subsp. *silvaticum*, *M. avium* subsp. *hominissuis* and *M. avium* subsp. *paratuberculosis* [21, 25, 29]. MAC may cause progressive parenchymal lung disease and bronchiectasis in patients, particularly in middle-aged and elderly women without underlying lung diseases [30]. Fibrocavitary lung disease caused by MAC may associated with large cavities specially in late 1940s and early 1950s years, males who have a history of cigarette smoking and excessive alcohol use. Untreated form of this disease is generally progressive to extensive cavitary lung destruction and respiratory failure within 1–2 years. MAC lung disease also presents with nodular and interstitial nodular infiltrates frequently involving the right middle lobe or lingual, called as nodular bronchiectasis or nodular bronchiectatic disease [31]. Particular MAC species may have varying degrees of virulence and classifying MAC isolates into species level is important for identification of risk of clinical relapse/reinfection [32, 33].

Tap water is likely the major reservoir for *M. kansasii* causing human pulmonary disease [34]. Genotypic studies in Netherland and France have shown that isolates recovered from the patients have similar genotype to isolates from drinking water source and the environment [35, 36]. DNA sequencing of *M. kansasii* has confirmed the presence of seven subspecies, which are related to human infections [37], while subtype 1 is the predominant in human lung infections [37–39]. Clinical symptoms of *M. kansasii* lung disease are generally identical to those associated with pulmonary TB. Chest radiographic abnormalities are also very similar to reactivation of pulmonary TB, including cavitary infiltrates with an upper lobe predilection. Also, *M. kansasii* may show noncavitary or nodular/bronchiectatic lung disease [40], which is similar to clinical presentation of MAC.

Some studies have been strengthened that drinking water may be the source of infection of *M. abscessus* lung diseases [41]. The common clinical symptoms of *M. abscessus* and *M. fortuitum* infection are similar to other NTM respiratory pathogens, especially MAC, including cough and easy fatigability. Disease caused by *M. genavense* commonly has been recognized in acquired immunodeficiency syndrome (AIDS) patients, while observed also in HIV-negative patient with pulmonary nodules [42].

Although most NTM lung infections are caused by common organisms, other NTM species such as *M. flavescens*, *M. mucogenicum* [26, 43], *M. colombiense*, *M. genavense*, *M. holsaticum*, *M. kumamotonense*, *M. lentiflavum*, *M. mantenii*, *M. marseillense*, *M. monacense*, *M. neoaurum*, *M. parascrofulaceum*, *M. phocaicum*, *M. saskatchewanense*, *M. seoulense*, *M. septicum*, *M. setense*, *M. shimoidi*, *M. stomatepiae*, *M. szulgai*, *M. triplex* [44], *M. xenopi*, *M. malmoense*, *M. immunogenum* [45], *M. scrofulaceum*, *M. terrae* complex, *M. engbaeki*, *M. shimoidi*, *M. gilvum*, *M. marinum*, *M. interjectum* subspecies, *M. heckeshornense*, *M. branderi* and *M. chromogen* [24] may cause pulmonary disease in both immunocompetent and immunocompromised patients.

Isolation of multiple NTM species from respiratory specimens has also been recorded. In Taiwan, two patients of 298, one had five isolates of MAC and one isolate of *M. fortuitum*, while another patient had 11 isolates of MAC and one isolate of *M. goodii* [27]. Thus, the pathogenic significance of a NTM specimen must be determined in the context of a patient's clinical presentation.

3. Prevalence and current epidemiology of pulmonary NTM disease

In Western societies, most laboratories report a dramatically greater prevalence of NTM than TB [46]. However, the prevalence of NTM pulmonary infections, which based on laboratory records, should be coupled with clinical characteristics [47] as only approximately half of people with positive NTM cultures fulfilled clinical criteria for active infection [48]. Studies from North America, Australia, South Korea, Japan and Taiwan have shown the continued increase in NTM prevalence since 2000. The annual prevalence in North America and Australia ranges from 3.2 to 9.8 per 100,000 and is generally higher than in Europe. In Queensland, Australia, cases of pulmonary disease rose from 2.2 to 3.2 per 100,000 population [49] during 1999–2005. Furthermore, in Australia, the annual percent of NTM isolation has increased steadily every year, and the incidence rate of patients with NTM lung disease was 1.82 per 100,000 in 2006 and increased to 4.38 per 100,000 in 2010 [50], while the same changed from 9.4 per 100,000 in 2009 to 36.1 per 100,000 in 2016 [51]. In Africa and the Middle East, prevalence of NTM ranges from 4 to 15% among suspected TB cases and 18% to 20% among suspected multidrug-resistant TB (MDR-TB) cases [52]. The prevalence rate of NTMPD in Germany was increased from 2.3 to 3.3 cases per 100,000 population from 2009 to 2014, and this was strongly association with advanced age and chronic obstructive pulmonary disease [53]. The prevalence of NTM isolation approximately was doubled from 2005 (6%) to 2013 (11%) in Hawaii, USA [26], while in Oregon, USA, the estimated prevalence of NTMPD was 8.6 per 100,000 [48]. By 2014, in Japan, the incidence rate of NTMPD was 14.7 cases per 100,000 person, which was ≈ 2.6 times higher than the same reported in 2007 and current incidence rate of NTMPD may exceed that of TB in Japan [48]. The general prevalence of NTM was 477 per 100,000 in Zambia with the regional variation of rate of prevalence within the country [54]. In Korea, the rates of recovery of NTM from clinical specimens and the number of patients with NTM lung infections increased significantly between 2009 and 2015 [55].

While some species such as MAC and *M. abscessus* are commonly implicated worldwide, others (e.g., *M. malmoense*, *M. xenopi*) are regionally important [23]. Generally, MAC is predominant in North America and East Asia, whereas *M. kansasii*, *M. xenopi* and *M. malmoense* are more common in Europe [52]. In Hawaii, USA, the most prevalent species was MAC, *M. fortuitum* group and *M. abscessus* [26]. Even though isolation of slowly growing mycobacteria (SGM) is frequent in most of the European and Western countries, rapidly growing mycobacteria (RGM) species such as *M. fortuitum* and *M. abscessus* are more prevalent in Gulf Cooperation Council (GCC) except in few countries [56]. As examples, *M. fortuitum* was the predominant course of NTM lung disease in Middle East during 1984–2014 [57]. Furthermore, *M. fortuitum* and *M. abscessus* are predominant in Saudi Arabia, while MAC is the most common species in Oman [56]. However, it has been observed in Saudi Arabia that rare species are going to be prominent, alarming diversity of clinically relevant NTM's causing pulmonary infections [58].

Country (no. of infections tested)	NTM species (%)								
	<i>M. abscessus</i>	<i>M. avium</i>	<i>M. chelonae</i>	<i>M. fortuitum</i>	<i>M. gordonae</i>	<i>M. kansatii</i>	<i>M. triviale</i>	<i>M. scrofulaceum</i>	<i>M. szulgai</i>
India (15)	–	–	–	40	–	33	20	–	7
Hong Kong (28)	–	54	14	–	4	4	–	–	4
South Korea (131)	39	50	2	3	–	4	–	–	0
Japan (1064)	–	81	0.6	2	–	14	–	–	0.5
Thailand (132)	–	43	5	5	–	17	–	8	–
Singapore (15)	–	60	7	–	–	27	–	7	–
Taiwan (302)	19	43	10	10	–	9	–	–	–

Table 1. NTM species causing pulmonary infections in Asian region during 1971–2007 [20].

The most frequent NTM species were *M. intracellulare* followed by *M. avium* subspecies in South Africa by 2010 [59], while *M. kansasii* is the more frequently associated among definite or probable active TB patients. Also, *M. avium-intracellulare* complex was the prominent course of NTM lung infections in Greece during 2007–2013 [60].

Furthermore, clinical relevance of pulmonary NTM species shows not only the geographically heterogeneous but also the time-to-time variations. As examples, MAC was the main cause of pulmonary diseases in India during the period of 1971–2007 [20]. But, according to the recent publications, *M. abscessus* was the predominate species followed by *M. intracellulare* [61, 62] in India, even both of the species were not recorded till 2007 [20] (Table 1). *M. intracellulare* followed by *M. kansasii* were most common NTM species related to the NTMPD in China from 2004 to 2009 [63] and it changed in 2010–2015 period, as *M. kansasii* was replaced by *M. abscessus* [64, 65]. Similar observation had been in Japan where, dramatic increases of pulmonary *M. abscessus* incidence had been occurred [48] comparative to period of 2001–2007.

Furthermore, in Korea, *M. intracellulare* followed by *M. avium* was predominate species during 2009–2015, while it was *M. avium* followed by *M. abscessus* in earlier (Table 1) [55].

4. Host-pathogen interactions

Unlike TB, the mode of transmission of NTM to humans has not been defined. Bathroom showers have been implicated as a primary source of exposure to aerosolized NTM. Even though animals are potential reservoir for NTM infections, zoonosis is not properly evident yet. However, drinking untreated water and living in close contact with cattle or other domestic animals may lead of infection in human [66]. In USA, NTM diseases are more

associated with densely populated areas, suggesting the infective source as urban municipal water supply [67], while Japan suggesting the soil as the source for more patients who were farmers and gardeners [68]. Furthermore, characteristic gradient clustering of the ratios of *M. avium* and *M. intracellulare* has been observed in Japan, suggesting that environmental factors strongly affect the epidemiology of NTMPD [69].

The outcome of the respiratory NTM disease is a result of a complex interplay between microbial factors like particle size, number of organisms and duration of contact and host susceptibility factors such as immunity, genetic background, lung damages and chronic lung disease. The clinical presentation of NTM lung infections may be varied, including hypersensitivity pneumonitis (HP)-like granulomatous lung disease, cavitary (TB-like) disease and nodular bronchiectasis. A hypersensitivity pneumonitis (HP)-like granulomatous lung disease, with nontuberculous mycobacteria can be triggered by inhalation of NTM with hot water aerosols (hot-tub lung) from sources such as hot tubs/spas, showers and indoor swimming pools. This may have been the primary source of MAC infections in middle-aged women with subacute presentation of respiratory complaints and HIV patients in the United States [70]. While MAC is the most common NTM causing “hot tub lung,” *M. fortuitum* has also been rarely implicated [71]. Physicians need to be alerted to the possibility of hot tub lung being caused by various NTM species other than MAC. Furthermore, a case study has been confirmed *M. gordonae* as a potential pathogen in humidifier lungs [72].

Rarely, with underlying lung disease or smoking or prior TB, cavitary disease could be caused by multiple NTM species especially by MAC. This condition is different from the typical presentation of MAC pulmonary infections as they may have upper lobe cavity, as well as TB-like symptoms [73, 74]. Nodular bronchiectasis, which is often present with older nonsmoking female, is associated mostly with MAC. Sometimes, mixed infections of MAC and *M. abscessus* may lead to nodular bronchiectasis [75, 76]. In really, solitary pulmonary nodules (SPN) due to MAC infection also have been identified in some studies [74, 77, 78]. However, clinical outcome of the NTM diseases basically depends on the interactions between NTM and the host (**Figure 1**).

4.1. Host factors

Immunosuppressed hosts who may be associated with immunosuppressive HIV infection, hematological and lymphoproliferative malignancy, stem cell and solid organ transplant and inflammatory disorders treated with biologicals are highly vulnerable for pulmonary infections caused by *M. avium* and other nontuberculous species. Defense against *Mycobacterium* species

Figure 1. Interactions between NTM and the host that determine the clinical outcome.

is mediated by mononuclear phagocytes' ability to kill mycobacteria and secrete interleukin-12 (IL-12), augmented by interferon-gamma (IFN γ) secreting lymphocytes such as CD4⁺T cells. Human natural killer cells (NK) are important in host defense against *Mycobacterium* as it secretes cytokines that induce macrophages to inhibit the growth of bacteria within macrophages [79, 80]. Cytokines that induce IL-32 (newly described pro-inflammatory cytokine), such as interferon-gamma, IL-18, IL-12, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha, have considerable importance in mycobacterial immunity [81]. The alliance formed between IL-12 and IFN-gamma is essential for protective immunity against mycobacteria in human [82]. Therefore, genetic deficiencies in immunity mediated by IL-12 or IFN-gamma are highly susceptible to mycobacteria NTM infections in both individuals and familial clusterings of disease [79, 83].

IL-32 is expressed in multiple cell types in the lungs but particularly in the airway epithelial cells of patients with MAC pulmonary disease. Human airway epithelial cells (BEAS-2B) infected with *M. avium* produce IL-32 by a nuclear factor-kappa B-dependent mechanism. In both BEAS-2B cells and human monocyte-derived macrophages, exogenous IL-32 significantly reduced the growth of intracellular *M. avium* by increased apoptosis of infected cells. Thus, IL-32 not only facilitates host defense against MAC organisms but may also contribute to the airway inflammation associated with MAC pulmonary disease [81].

In immune evasion mechanism of *M. avium* subsp. paratuberculosis (MAP), bacteria are survived in macrophages by activation of mitogen-activated protein kinase (MAPK) pathway that leads to inhibition of antimicrobial activity of macrophages and over expression of IL-10. High levels of IL-10 in paratuberculosis promote the survival of MAP by reducing bactericidal activity of defense cells. Therefore, the pathways involved in the upregulation of IL-10 such as MAPK can be vital for developing a therapeutic strategy for the control of paratuberculosis [84]. A monogenic disorders conferring susceptibility to NTM infection are called as Mendelian Susceptibility to Mycobacterial Disease (MSMD) conditions, which are extremely rare and predominantly affecting children. Genetic disorders, which affect the immune response to mycobacterial infection, are known to result from disorders in genes of ISG15, IL-12B, IL12RB1, IFNGR1, IFNGR2, STAT1, IRF8, ISG-15, GATA2, NADPH and oxidase complex subunit genes such as CYBB [85].

Diseases and therapies that reduce cell-mediated immunity increase the risk of NTM disease. Acquired immunodeficiency virus (AIDS), cancer and organ transplants have been associated with NTM disease. The use of immunosuppressive drugs, including anti-TNF biologics, is also a risk factor for NTMPD [86]. NTM are often found in sputum cultures of patients with cystic fibrosis as they undergo lung transplantation followed by immunosuppressive medications. Therefore, effective medical treatment may need to control NTM after lung transplantation. The post-transplant infections can be associated with *M. abscessus*, which not affect for the survival of the patient in pre-transplantation stage. Therefore, sputum culture positivity for NTM before lung transplantation should not preclude transplantation, but should be treated in order to minimize the risk for recurrence after transplantation [87]. There is a possibility of co-existing pulmonary NTM infection in patients with lung cancer and disseminated NTM infection in patients with hematologic cancer [88, 89]. A study has suggested that anti-NTM therapy should be introduced only with worsening of symptoms under careful consideration as anti-NTM treatment is long and anti-mycobacterial drugs have extensive effects on anti-cancer drugs [90].

Also female sex, age, post-menopausal waning of endogenous estrogen levels, coeliac disease and exposure to use of dietary phytoestrogens can be risk factors for NTM lung diseases [91] while oral corticosteroids treatment in rheumatoid arthritis patients is also a comorbidity of NTM disease [92]. However, another study has showed that bronchiectasis and NTM lung disease are risk factors for breast cancer in women, and this phenomenon will open a new pathway for investigation of common pathophysiologic links of NTMPD [93].

4.2. Microbial factors

Aside from host factors, microbial factors such as virulence and microbial dose of exposed would be considerable factors for progression of NTM lung diseases. The critical exposure dose and relationship between quantitative mycobacterial exposure and disease are yet to be known. However, it may vary with the host susceptibility. Although exposure is common, disease is unusual, as most of NTM species are nonpathogenic and pathogenicities are varied according to the NTM species. Only few are highly pathogenic in human in descending order of pathogenicity, *M. malmoense*, *M. szulgai*, *M. kansasii*, *M. abscessus*, *M. Xenopi*, *M. avium* and *M. simiae*/*M. chelonae* and *M. intracellulare*. Even though MAC account for the plurality of pulmonary isolates as well as disease worldwide, the clinical relevance of NTM isolation from respiratory specimens appears to vary by geographic region, presumably due to variability in both environmental microbial distribution and the prevalence of host risk factors [23].

5. Diagnosis of NTM lung infections

Unlike TB, the isolation of NTM in pulmonary specimens does not equate with disease. The guidelines published in 2007 by American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) (ATS/IDSA) have specified that both clinical and microbiologic criteria must be met for the confirmation of diagnosis of pulmonary NTM disease [22]. Also, correct species identification is vital as NTM species differ in their clinical relevance. Correct diagnosis and choice of treatment regimen are needed as to prevent misdiagnosis, which direct chronic disease, antimicrobial resistance and death [94]. However, identification of all clinically obtained NTM isolates, especially from sputum, may not be needed. For instance, the exact identification of a pigmented rapidly growing mycobacteria isolated in low numbers from only one of multiple sputum specimens collected from patient undergoing therapy for MAC lung disease may not be necessary as it would not likely be clinically significant [22]. The diagnosis requires the presence of symptoms, radiographic abnormalities or chest high resolution computed tomography (HRCT) scan in the absence of cavitations, three or more sputum specimens for acid fast bacilli (AFB) analysis and exclusion of other disorders such as TB and lung malignancy. According to the ATS/IDSA guidelines, the criteria apply for definitive diagnosing of nontuberculous mycobacterial lung disease is following [22].

Clinical (both required)

1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph or an (HRCT) scan that shows multifocal bronchiectasis with multiple small nodules.
2. Appropriate exclusion of other diagnoses.

Microbiologic.

1. Positive culture results from at least two separate expectorated sputum samples. (If the results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB smears and cultures.) (or)
2. Positive culture results from at least one bronchial wash or lavage (or)
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the diagnostic criteria should be followed until the diagnosis is firmly established or excluded.
6. Making the diagnosis of NTM lung disease does not, *per se*, necessitate the institution of therapy, which is a decision based on potential risks and benefits of therapy for individual patients.

5.1. Clinical and radiographic based diagnosis

Delaying of diagnosis of NTM lung diseases is frequent due to the slow growing rate, misdiagnosed as TB or other AFB-positive bacilli and low index of clinical suspicion. The clinical symptoms, such as chronic cough, increased sputum production, dyspnea, low-grade fever, malaise and weight loss, are often nonspecific and overlapping clinical characteristics with pulmonary TB [95].

Radiological imaging and observing of radiological patterns, including miliary pulmonary pattern, nodular lesions, cavitary lesions, pleural effusion, abdominal adenopathy and splenic hypoechoic, is important when NTM lung disease is suspected in AIDS patients [96]. HRCT scanning allows early detection and better differentiation between colonization and invasive infection that are not visible on the chest X-ray [97]. In CT features; pleural effusion and nodules are significantly more common in patients with pulmonary TB (PTB) while bronchiectasis combined with cystic changes are significantly more common in patients with NTM lung infections [98]. Bronchiectasis in the right middle lobe or left lingual segment and thin-walled cavity with a diameter of more than 3 cm are the frequent chest CT features in patients with NTM-LD [99]. Furthermore, cavities associated with adjacent pleural thickening, ill-defined satellite tree-in-bud nodules or fewer noncavitary nodules in CT findings are highly suggestive of NTM disease rather than TB [58, 100].

Also, NTM lung infection can present itself with different radiological patterns, while two main patterns, fibrocavitory form and nodular bronchiectatic form, have been observed frequently [100]. The fibrocavitory form is usually characterized by upper lobe cavities with areas of increased opacity and with or without calcification (**Figure 2**) [98, 101].

Figure 2. CT of fibrocavitary form of *M. intracellulare* pulmonary disease with a large cavity in the right upper lobe [101].

In the nodular bronchiectatic form: bilateral, multilobar bronchiectasis, especially in the middle and lower lung fields, with small nodules are the frequently observed chest CT features (**Figure 3**) [99, 101].

Even though there are no characteristic radiographic patterns for individual NTM species, centrilobular, peribronchovascular nodules, bronchiectasis, consolidation, tree-in-bud, pleural thickening and pleural adhesion are commonly observed CT findings in patients with MAC infection [102]. A recent study has shown that cavities are more common in patients with *M. malmoense*, while consolidations are mostly found among patients with an MAC and nodules are frequent in *M. kansasii* patients [103]. However, due to the presence of considerable overlap of the clinical symptoms and radiographic appearances of PTB and NTM lung diseases, the isolation and identification of causative organisms are mandatory for correct diagnosis of patients with AFB-positive sputum specimens [76].

Figure 3. CT of nodular bronchiectatic form of *M. intracellulare* pulmonary disease with severe bronchiectasis in the right middle lobe and the lingular segment of the left upper lobe [101].

5.2. Laboratory diagnosis

The initial laboratory identification of the genus *Mycobacterium* can be made by microscopic observation for the presence of AFB. The definitive diagnosis demands the recovery of *Mycobacterium* species on a culture medium, followed by species identification tests. Although numerous novel, rapid and direct molecular methods have been developed, culture remains the gold standard for identification of *Mycobacterium* species from clinical specimens [104].

5.2.1. AFB smear microscopy

AFB staining, such as fluorochrome technique, Ziehl-Neelsen method or Kinyoun stain, which initially adopted for identification of *Mycobacterium tuberculosis* complex (MTBC), is satisfactory for NTM also. However, Smear microscopy cannot use for differentiation of MTBC from NTM, hence the presence of AFB can lead to a false-positive diagnosis of TB. The burden of organisms in clinical material is usually reflected by the number of organisms seen on stained smears. Since NTM are present in the environment, especially in water sources, the careful collection of high-quality respiratory specimens is necessary to avoid contamination. However, environmental contamination, which usually involves small numbers of organisms, rarely results in a positive smear examination. Semi-quantitative analysis of smears can be useful for diagnostic purposes and fluorochrome smears are graded from 1 (1–9 organisms per 10 high-power fields) to 4 (90 organisms per high-power field) [101, 105, 106].

5.2.2. *Mycobacterium* culture and species identification by conventional methods

Isolation of *Mycobacterium* by culturing is a primary requirement in conventional species identification and indirect drug susceptibility testing of NTM. The general microbiological measures of growing clinical material on a selective or differential culture media and sub-culturing to obtain pure cultures cannot be applied to *Mycobacterium*. Genus *Mycobacterium* will not grow on simple, chemically defined media and it requires special, enriched, selective media. Also, slow replication rate is a characteristic feature in culturing of *Mycobacterium*, hence culturing is time-consuming [107]. Generally, an AFB-positive sputum will require 3 weeks for producing visible colonies of *Mycobacterium* on solid medium [4]. However, NTM species, such as *M. fortuitum*, *M. abscessus* and *M. chelonae*, are considered as rapid growers as they grow into visible colonies within 3–5 days of incubation [19, 22].

As per ATS/IDSA guidelines, both solid and liquid cultures are required for NTM species identification. Even though mycobacteria produce more rapid cultures with high yield in broth media than those on solid media, solid cultures need to proceed simultaneously as they allow observing of colony morphology, growth rates and mixed infections (more than one mycobacterial species), which are important factors in identification of the NTM species. Also, broth media cultures alone may not be sufficient for better diagnosis of NTM species due to the bacterial overgrowth and high chance for the contaminations from other bacteria and fungus [22].

In conventional culture techniques, Lowenstein-Jensen (LJ) media and agar-based Middlebrook media (7H10 and 7H11) are used as the common solid media, while 7H9 medium used as the liquid/broth media. BACTEC MGIT 960 system is a fully automated, nonradiometric system that is suitable for the detection of growth of TB and other mycobacteria with the shorter

detection time ~2 weeks [108]. The recently introduced, microchannel electrical impedance spectroscopy (m-EIS) has ability to detect *M. smegmatis* with initial loads of 1000 CFU/ml within 20 h, while commercial BACTEC MGIT 960 system need 41.7 h for the same [109].

Species, such as *M. haemophilum*, *M. genavense*, *M. avium* subsp. paratuberculosis (formerly *M. paratuberculosis*) and *M. ulcerans*, are required special supplementation for recovery on culture media. *M. haemophilum* grows only on media supplemented with iron-containing compounds such as ferric ammonium citrate, hemin or hemoglobin [110]. *M. genavense* and *M. avium* subsp. paratuberculosis require mycobactin J, and *M. ulcerans* may be optimally recovered with egg yolk supplementation [22].

Microscopic observation of ZN-stained smear prepared from culture will provide evidence only for the presence of mycobacteria, purity of the culture and cord formation. These basic characters are not sufficient for definitive species level identification. The conventional taxonomic differentiation of the genus *Mycobacterium* is based on phenotypic characters of the cultures and biochemical properties of bacteria. The characters of rapid growth, pigmentation (scotochromogens, photochromogens or nonchromogens), ability to grow in PNB incorporated media and creamy like watery colonies indicate the presence of NTM [107]. Several biochemical tests based on the properties of the genus *Mycobacterium*, including nitrate reductase, niacin production, catalase activity, production of arylsulfatase and urease, tween 80 hydrolysis, growth in the presence of 5% NaCl and MacConkey agar without crystal violet and the use of mannitol, inositol and sorbitol, may adequate to identify majority of clinically relevant mycobacterial species [107].

5.2.3. Molecular-based identification methods

Biochemical analysis and phenotypic characters may occasionally fail to arrive at a definitive identification. Because of differences in antimicrobial susceptibility at species level that determine treatment options, precise species identification of the NTM is required and only determination of merely as groups, such as *M. chelonae* (or/and *M. abscessus*) group, is not recommended [22]. To fulfill this requirement, rapid accurate and cost-effective molecular-based techniques, both *in-house* and commercial kits, with satisfied sensitivity and specificity were developed during last years. Currently, molecular methods especially assays based on the principle of nucleic acid amplification which allows a speedy and precise identification of the *Mycobacterium* species in <24 h have been developed.

Real-time PCR, DNA sequencing, probe hybridization, multiplex PCR and polymorphism analysis of restriction fragments (PCR-RFLP) are commonly used for differentiation of NTM species related to lung infections [111, 112]. The real-time PCR assays are advantageous because of its rapidity and high sensitivity. Furthermore, the specificity of the real-time PCR can be enhanced by combination with HPLC, which is a useful tool to discriminate NTM at the species level, although it requires specific equipment and technical expertise [113]. Furthermore, multiplex real-time PCR assay combined with melting curve analysis is also an accurate, rapid and effective tool for the mycobacterial identification from cultures [114]. The commercial form of real-time PCR Light cycler® *Mycobacterium* detection assay, which based on the 16S ribosomal RNA (rRNA), has shown 100% sensitivity and 99% specificity for differentiation of MTBC and *M. avium* from sputum samples [115, 116].

Several commercial kits, which are based on PCR amplification of selected fragment of 16S or 23S rRNA gene or 16S–23S rRNA spacer region, followed by reverse hybridization on nitrocellulose membrane strips such as GenoType *Mycobacterium* CM/AS (Hain Lifescience, Nehren, Germany) [117–120] and INNO-LiPA Mycobacteria (LiPA; Innogenetics, Zwijnaarde, Belgium) [121, 122] are available for identification of common pathogenic NTM species with high sensitivity and specificity. Genus *Mycobacterium*, MTBC and 16 NTM species are identified by INNO-LiPA mycobacteria assay, and it is based on the nucleotide variations in the 16S–23S rRNA spacer region (**Figure 4**).

Mixed populations easily identified with this assay and fully automated processing of the strips is possible using TENDIGO™ and Auto-LiPA 48. GenoType *Mycobacterium* CM kit identifies

Figure 4. Location of the different probes on the INNO-LiPA Mycobacteria v2 strip.

the MTBC and differentiates of 27 clinically relevant NTM, while GenoType *Mycobacterium* AS kit enables the differentiation of 19 additional NTM species (Figures 5 and 6).

Direct sequence analysis of amplified 16S rRNA gene is a promising rapid and accurate method for species determination of nontuberculous mycobacteria [123], and in last decades, novel NTM species related to pulmonary infections were identified by this technique. In addition to that, several gene targets, including *rpoB* gene [124–126], *secA1* gene [127] and *hsp65*

Figure 5. Location of the different probes on the GenoType *Mycobacterium* AS strip.

Figure 6. Location of the different probes on the GenoType *Mycobacterium* CM strip.

gene [128], have used for NTM species identification by DNA sequencing. Also, *gyrB*-based microarray [129], mycobacteria mobility shift assay (MMSA) [130], biochip assay system [131] and multiplex SNaPshot assay [132] have been proven as rapid detection methods to identify closely related mycobacterial species with satisfied level of sensitivity and specificity, which may be useful in the diagnosis and effective management of NTM lung disease [129–132].

6. Antimicrobial susceptibility testing for NTM

The laboratory susceptibility testing of pulmonary infective NTM species are based on the ATS/IDSA and Clinical and Laboratory Standards Institute (CLSI) guidelines. CLSI has recommended broth microdilution method as the gold standard for laboratories where antimicrobial susceptibility testing of NTM is performed [133]. There are no current recommendations for a specific method of *in vitro* susceptibility testing for fastidious NTM species and some less commonly isolated NTM species. Validation and quality control should be in place for susceptibility testing of antimicrobial agents with all species of NTM. According to the diagnostic guidelines for nontuberculous mycobacteria which are recommended by the ATS [22], only the Clarithromycin should be tested for susceptibility for new, previously untreated MAC isolates and susceptibility testes for other drugs are not recommended. Also, MAC isolates from patients who fail macrolide treatment or prophylaxis regimens should be tested to clarithromycin susceptibility. Isolates of *M. kansasii* that show susceptibility to rifampin will also be susceptible to rifabutin. Therefore, previously untreated *M. kansasii* strains should be tested *in vitro* only to rifampin. The rifampin resistant of *M. kansasii* isolates should be tested against a panel of secondary agents, including rifabutin, ethambutol, isoniazid, clarithromycin, fluoroquinolones, amikacin and sulfonamides. Unless the patient fails treatment after several months, *M. marinum* isolates do not require susceptibility testing.

The *in vitro* susceptibility patterns of some NTM such as *M. kansasii*, *M. marinum* and *M. fortuitum* are closely parallel to the clinical response to therapeutic agents. But, MAC, *M. abscessus* and *M. simiae* have limited evidences for the correlation between *in vitro* susceptibility results and clinical response in the treatment of pulmonary disease caused by these agents [134]. Furthermore, antimicrobial susceptibility patterns of rapidly growing mycobacteria (RGM) including isolates of the *M. fortuitum* group, *M. chelonae* and *M. abscessus* provide taxonomical value also in addition to the evidence of drug resistance [135].

According to the recent publications, the microplate Alamar Blue assay [136] and tetrazolium Microplate Assay [137] have also shown reliable results to the recommended microdilution method. However, molecular assays have not yet been able to replace time-consuming culture-based susceptibility methods in the mycobacteriology laboratory.

7. Treatment of NTM lung infections

After determination of the clinical significance of a NTM species, patient should be treated with appropriated antimicrobial regimen. The duration of treatment for most pulmonary NTM pathogens is based on treatment recommendations. Frequently encountered species

such as MAC and *M. kansasii* are treated 12 months of negative sputum cultures while on therapy. For disseminated disease, treatment duration for most NTM pathogens is the same as for disseminated MAC infection.

Treatment recommendations for infrequently encountered NTM are made on the basis of only a few reported cases. As recommendations for routine *in vitro* susceptibility testing of NTM isolates are limited, the clinician should use *in vitro* susceptibility data with an appreciation for its limitations. Empiric therapy for suspected NTM lung disease is not recommended. Furthermore, there are no widely accepted criteria for choosing patients with NTM lung disease for resectional surgery. In generally, surgery could be considered based on risk/benefit perspective in case of NTM infections that are more difficult to treat medically [22].

7.1. *M. avium* complex (MAC)

Drug therapy for MAC lung disease should be a combination of several antibiotics (Table 2), and the optimal therapeutic regimen has yet to be established [22].

Special recommendations of drug regimens are needed for patients with intolerance to first-line agents, a macrolide-resistant MAC cases or failed prior drug therapy. The macrolides should never be used as monotherapy for treatment of MAC lung disease. The duration of the treatment is 12 months of negative sputum cultures while on therapy; hence continuous observation of AFB in sputum of the patient is required throughout the treatment [22, 138]. The addition of intramuscular streptomycin to standard regimen for the first 3 months of treatment for MAC pulmonary disease improves the rate of culture conversion, even though clinical response and radiological outcome are not significantly improved. An intermittent (3× per week) oral antibiotic regimen should not be used in individuals with severe MAC pulmonary disease or in individuals with a history of treatment failure [138].

Major risk factors for macrolide-resistant MAC disease are inappropriate prescription patterns and deviations from the standard treatment due to adverse drug reactions [139]. More

Drug	Initial therapy for nodular/bronchiectatic disease	Initial therapy for cavitary disease	Advance or previously treated disease
Macrolide	Clarithromycin 1000 mg TIW or azithromycin 500–600 mg TIW	Clarithromycin 500*–1000 mg/d or azithromycin 250–300 mg/d	Clarithromycin 500*–1000 mg/d or azithromycin
Ethambutol	25 mg/kg TIW	15 mg/kg/d	15 mg/kg/d
Rifamycin	Rifampin 600 mg TIW	Rifampin 450*–600 mg/d	Rifabutin 150*–300 mg/d or rifampin 450*–600 mg/d
IV aminoglycoside	None	Streptomycin or amikacin or none	Streptomycin or amikacin

Notes: IV = intravenous; TIW = three times weekly. *Lower dose for weight 50 kg.

Table 2. Recommended antimicrobial combination [138].

effective therapy is essential to treat and prevent macrolide-resistant with MAC lung disease [140]. Antibiotic treatment associated with rifampicin, ethambutol and isoniazid or a quinolone with streptomycin or amikacin and surgical resection of disease can be used in macrolide-resistant MAC diseases [31, 101, 138, 140]. Furthermore, the addition of moxifloxacin can improve the outcomes of patients with macrolide-resistant [141]. However, recent study has shown that continuation of macrolides or the addition of a new quinolone or injectable aminoglycoside to therapy with rifampicin and ethambutol would not improve clinical outcome

Species	Drug regimen	Duration
<i>M. kansasii</i> – Rifampicin-sensitive	Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + Isoniazid 300 mg (with pyridoxine 10 mg) daily or Azithromycin 250 mg daily or Clarithromycin 500 mg twice daily	12 months after culture conversion.
<i>M. malmoense</i>	<i>Non-severe disease:</i> Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + Azithromycin 250 mg daily or Clarithromycin 500 mg twice daily <i>Severe M. malmoense-pulmonary disease:</i> Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + Azithromycin 250 mg daily or Clarithromycin 500 mg twice daily + consider intravenous amikacin for up to 3 months or nebulized amikacin	Minimum of 12 months after culture conversion Minimum of 12 months after culture conversion
<i>M. xenopi</i>	<i>Non-severe</i> Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + Azithromycin 250 mg daily or Clarithromycin 500 mg twice daily + Moxifloxacin 400 mg daily or Isoniazid 300 mg (+ pyridoxine 10 mg) daily <i>Severe</i> Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + Azithromycin 250 mg daily or Clarithromycin 500 mg twice daily + Moxifloxacin 400 mg daily or Isoniazid 300 mg (+ pyridoxine 10 mg) daily + consider intravenous amikacin for up to 3 months or nebulized amikacin	Minimum of 12 months after culture conversion Minimum of 12 months after culture conversion
<i>M. abscessus</i> Clarithromycin sensitive isolates or inducible macrolide-resistant cases	<i>Initial phase:</i> ≥1 month iv amikacin 15 mg/kg daily or 3× per week + iv tigecycline 50 mg twice daily and where tolerated iv imipenem 1 g twice daily and where tolerated oral clarithromycin 500 mg twice daily or oral azithromycin 250–500 mg daily <i>Continuation phase:</i> Nebulized amikacin + oral clarithromycin 500 mg twice daily or azithromycin 250–500 mg daily +1–3 of the following antibiotics guided by drug susceptibility results + patient tolerance: oral clofazimine 50–100 mg daily, oral linezolid 600 mg daily or twice daily (with pyridoxine 50 mg daily), oral minocycline 100 mg twice daily, oral moxifloxacin 400 mg daily, oral co-trimoxazole 960 mg twice daily	Minimum of 12 months after culture conversion

Species	Drug regimen	Duration
<i>M. abscessus</i> Constitutive macrolide-resistant cases	<i>Initial phase:</i> ≥1 month iv amikacin 15 mg/kg daily or 3× per week and iv tigecycline 50 mg twice daily + where tolerated iv imipenem 1 g twice daily	Minimum of 12 months after culture conversion
	<i>Continuation phase:</i> Nebulised amikacin and 2–4 of the following antibiotics guided by drug susceptibility results + patient tolerance: oral clofazimine 50–100 mg daily, oral linezolid 600 mg daily or twice daily (with pyridoxine 50 mg daily), oral minocycline 100 mg twice daily, oral moxifloxacin 400 mg daily, oral co-trimoxazole 960 mg twice daily	

Note: iv = intravenous.

Table 3. Recommended treatment regimen for *M. kansasii*, *M. malmoense*, *M. xenopi* and *M. abscessus* pulmonary diseases [138].

after the emergence of chloramphenicol-resistant MAC [142]. If microbiologic, clinical or radiographic improvements are not shown after 6 months of appropriate therapy or achieved conversion of sputum to AFB culture negative after 12 months of appropriate therapy, patients are considered as treatment failures [22].

In addition to antibiotics, for patients with MAC lung infection, adjunctive therapies may also be given. Patients whose disease is predominantly localized to one lung, poor response to drug therapy, the development of macrolide-resistant MAC disease or the presence of significant disease-related complications such as hemoptysis might be considered for surgery. Although adjuvant pulmonary resection is complicated, it provides high level of treatment success rate in selected patients [143, 144]. Successful treatment of disseminated MAC in persons with AIDS is based on treatment of both the mycobacterial infection and the HIV infection. Both clarithromycin and azithromycin have been shown to be effective in combination regimens for the treatment of disseminated MAC. But, treatment of these cases may be complicated by adverse drug effects [22, 145].

Recommended treatment regimen for *M. kansasii*, *M. malmoense*, *M. xenopi* and *M. abscessus* is described in **Table 3**. The treatment for *M. abscessus* pulmonary disease should comprise an initial phase antibiotic regimen followed by a continuation phase antibiotic regimen. However, individuals with a history of treatment intolerance or treatment failure should be managed in collaboration with a physician experienced in managing NTMPD.

Author details

Chamila Priyangani Adikaram

Address all correspondence to: chamilaadhikaram@yahoo.com

Central Public Health Laboratories, Ministry of Health, Muscat, Oman

References

- [1] Skerman VBD, McGowan V, Sneath PHA. Approved lists of bacterial names. International Journal of Systematic Bacteriology. 1980;**30**:225-420
- [2] Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-Tuberculous mycobacteria. Respiration. 2016;**91**:386-402. DOI: 10.1159/000445906
- [3] Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. Journal of Thoracic Disease. 2014;**6**:210-220. DOI: 10.3978/j.issn.2072-1439.2013.12.24
- [4] Palomino JC, Leao SC, Ritacco V. Tuberculosis 2007: From Basic Science to Patient Care. 1st ed. TuberculosisTextbook.com, 2007. Available from: <http://www.freebooks4doctors.com/pdf/tuberculosis2007.pdf>
- [5] Wieten G, Haverkamp J, Groothuis DG, Berwald LG, David HL. Classification and identification of *Mycobacterium africanum* by pyrolysis mass spectrometry. Journal of General Microbiology.. 1983;**129**:3679-3688
- [6] Pfyffer GE, Auckenthaler R, van Embden JDA, van Soolingen D. *Mycobacterium canettii*, the smooth variant of *M. tuberculosis*, isolated from a Swiss patient exposed in Africa. Emerging Infectious Diseases. 1998;**4**:631-634
- [7] Arana ZA, Leibana E, Gomes-Mampaso E. *Mycobacterium tuberculosis* subsp. caprae subsp. nov.: A taxonomic study of a new member of the *Mycobacterium tuberculosis* complex isolated from goats in Spain. International Journal of Systematic and Evolutionary Microbiology. 1999;**49**:1263-1263
- [8] Cousins DV, Bastida R, Cataldi A. Tuberculosis in seals caused by a novel member of the *Mycobacterium tuberculosis* complex: *Mycobacterium pinnipedii* sp. nov. International Journal of Systematic and Evolutionary Microbiology. 2003;**53**:1305-1304
- [9] Alexander KA, Laver PN, Michel AL, Williams M, van Helden PD, Warren RM, van Pittius NCG. Novel *Mycobacterium tuberculosis* complex pathogen, *M. mungi*. Emerging Infectious Diseases. 2010;**16**:1296-1299. DOI: 10.3201/eid1608.100314
- [10] Dawson KL, Bell A, Kawakami P, Coley K, Yates G, Collins DM. Transmission of *Mycobacterium orygis* (*M. tuberculosis* complex species) from a tuberculosis patient to a dairy cow in New Zealand. Journal of Clinical Microbiology. 2012;**50**:3136-3138
- [11] Parsons SDC, Drewe JA, van Pittius NCG, Warren RM, van Helden PD. Novel cause of tuberculosis in Meerkats, South Africa. Emerging Infectious Diseases. 2013;**19**:2004-2007
- [12] Moda G, Daborn CJ, Grange JM, Cosivi O. The zoonotic importance of *Mycobacterium bovis*. Tubercle and Lung Disease. 1996;**77**:103-108
- [13] Cavanagh R, Begon M, Bennett M, et al. *Mycobacterium microti* infection (vole tuberculosis) in wild rodent populations. Journal of Clinical Microbiology. 2002;**40**:3281-3285
- [14] Cvetnic Z, Katalinic-Jankovic V, Sostaric B, et al. *Mycobacterium caprae* in cattle and humans in Croatia. The International Journal of Tuberculosis and Lung Disease. 2007;**11**:652-658

- [15] Kiers A, Klarenbeek A, Mendelits B, Van Soolingen D, Koeter G. Transmission of *Mycobacterium pinnipedii* to humans in a zoo with marine mammals. *International Journal of Tuberculosis and Lung Disease*. 2008;**12**:1469-1463
- [16] De Jong BC, Adetifa I, Walther B, et al. Differences between TB cases infected with *M. africanum*, West-African type 2, relative to Euro-American *M. tuberculosis*- an update. *FEMS Immunology & Medical Microbiology*. 2010;**58**:102-105
- [17] Addo KK, Owusu-darko K, Yeboah-manu D et al. Mycobacterial species causing pulmonary tuberculosis at the Korle Bu teaching hospital, Accra, Ghana. *Ghana Medical Journal*. 2007;**41**:52-57
- [18] Wolinsky E. Mycobacterial diseases other than tuberculosis. *Clinical Infectious Diseases*. 1992;**15**:1-10
- [19] Falkinham JO. Nontuberculous mycobacteria in the environment. *Clinics in Chest Medicine*. 2002;**23**:529-551
- [20] Simons S, van Ingen J, Hsueh P-R, Van Hung N, Boeree PMJ, van Soolingen D. Nontuberculous mycobacteria in respiratory tract infections, Eastern Asia. *Emerging Infectious Diseases*. 2011;**17**:343-349. DOI: 10.3201/eid1703100604
- [21] Godreuil S, Marchandin H, Michon A-L et al. *Mycobacterium riyadhense* pulmonary infection, France and Bahrain. *Emerging Infectious Diseases*. 2012;**18**:176-178
- [22] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *American Journal of Respiratory and Critical Care Medicine*. 2007;**175**:367-414
- [23] Stout JE, Koh W-J, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. *International Journal of Infectious Diseases*. 2016;**45**:123-134
- [24] Pauls RJ, Turenne CY, Wolfe JN, Kabani A. A high proportion of novel mycobacteria species identified by 16S rDNA analysis among slowly growing AccuProbe-negative strains in a clinical setting. *American Journal of Clinical Pathology*. 2003;**120**:560-566
- [25] Loebinger MR, Welte T. Current perspectives in the diagnosis and treatment of non-tuberculous mycobacterial pulmonary disease. *European Respiratory & Pulmonary Diseases*. 2016;**2**:54-57. DOI: <http://doi.org/10.17925/ERPD.2016.02.02.54>
- [26] Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, Honda S, Prevots DR. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. *Emerging Infectious Diseases*. 2017;**23**:439-447. DOI: <http://dx.doi.org/10.3201/eid2303.161827>
- [27] Huang CT, Tsai YJ, Shu CC, Lei YC, Wang JY, Yud CJ, Lee LN, Yang PC. Clinical significance of isolation of nontuberculous mycobacteria in pulmonary tuberculosis patients. *Respiratory Medicine* 2009;**103**:1484-1491

- [28] Nishiuchi Y, Iwamoto T, Maruyama F. Infection sources of a common non-tuberculous mycobacterial pathogen, *Mycobacterium avium* complex. *Frontiers in Medicine*. 2017;**4**: 1-17. DOI: 10.3389/fmed.2017.00027
- [29] Cayrou C, Turenne C, Behr MA, Drancourt M. Genotyping of *Mycobacterium avium* Complex organisms using multispacer sequence typing. *Microbiology*. 2010;**156**:687-694. DOI: 10.1099/mic.0.033522-0. (Epub Nov 19, 2009)
- [30] Field SK, Fisher D, Cowie RL. *Mycobacterium avium* Complex pulmonary disease in patients without HIV infection. *Chest*. 2004;**126**:566-581
- [31] Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to *Mycobacterium avium* complex. *Seminars in Respiratory and Critical Care Medicine*. 2008;**29**:569-576
- [32] Amaral EP, Kipnis TL, de Carvalho ECQ, da Silva WD, Leão SC, et al. Difference in virulence of *Mycobacterium avium* isolates sharing indistinguishable DNA fingerprint determined in murine model of lung infection. *PLoS One*. 2011;**6**:e21673. DOI: 10.1371/journal.pone.0021673
- [33] Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among *Mycobacterium avium* complex species. *American Journal of Respiratory and Critical Care Medicine*. 2015;**191**:1310-1317
- [34] Griffith DE. Management of disease due to *Mycobacterium kansasii*. *Clinics in Chest Medicine*. 2002;**23**:613-621
- [35] Engel HWB, Berwald LG. The occurrence of *Mycobacterium kansasii* in tap water. *Tuberculosis*. 1980;**61**:21-26
- [36] Picardeau M, Prod'homme G, Raskine L, Lepennec MP, Vincent V. Genotypic characterization of five subspecies of *Mycobacterium kansasii*. *Journal of Clinical Microbiology*. 1997;**35**:25-32
- [37] Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, Frei R, Bassetti S, Rohner P, Piffaretti J-C, Bernasconi E, Bille J, Telenti A, Prod'homme G. Clinical implications of *Mycobacterium kansasii* species heterogeneity: Swiss National Survey. *Journal of Clinical Microbiology*. 2003;**41**:1240-1244
- [38] Zhang Y, Mann LB, Wilson RW, Brown-Elliott BA, Vincent V, Iinuma Y, Wallace RJ. Molecular analysis of *Mycobacterium kansasii* isolates from the United States. *Journal of Clinical Microbiology*. 2004;**42**:119-125. DOI: 10.1128/JCM.42.1.119-125.2004
- [39] Bakula Z, Safianowska A, Nowacka-Mazurek M, Bielecki J, Jagielski T. Short communication: Subtyping of *Mycobacterium kansasii* by PCR-restriction enzyme analysis of the hsp65 gene. *BioMed Research International*. 2013. DOI: <http://dx.doi.org/10.1155/2013/178725>
- [40] de Mello KGC, Mello FCQ, Borga L, Rolla V, Duarte RS, Sampaio EP, Holland SM, R Prevots. Dalcolmo M P. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011. *Emerging Infectious Diseases* 2013;**19**:393-399

- [41] Thomson R, Tolson C, Sidjabat H, Huygens F, Hargreaves M. *Mycobacterium abscessus* isolated from municipal water – A potential source of human infection. BMC Infectious Diseases. 2013;**13**:1-7. DOI: <http://www.biomedcentral.com/1471-2334/13/241>
- [42] Doggett JS, Strasfeld L. Disseminated *Mycobacterium genavense* with pulmonary nodules in a kidney transplant recipient: Case report and review of the literature. Transplant Infectious Disease. 2011;**13**:38-43. DOI: 10.1111/j.1399-3062.2010.00545.x
- [43] Ahmed I, Jabeen K, Hasan R. Identification of non-tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital: A cross-sectional study. BMC Infectious Diseases. 2013;**13**:493. DOI: <http://www.biomedcentral.com/1471-2334/13/493>
- [44] Liu H, Lian L, Jiang Y, Huang M, Tan Y, Zhao X, Zhang J, Yu Q, Liu J, Dong H, Lu B, Wu Y, Wan K. Identification of species of nontuberculous mycobacteria clinical isolates from 8 Provinces of China. BioMed Research International. 2016. DOI: <http://dx.doi.org/10.1155/2016/2153910>
- [45] Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clinical Microbiology and Infection. 2009;**10**:906-910. DOI: 10.1111/j.1469-0691.2009.03014.x
- [46] Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: A changing epidemiology. Clinical Infectious Diseases. 2009;**49**:124-129
- [47] Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Seminars in Respiratory and Critical Care Medicine. 2013; **34**:87-94. DOI: 10.1055/s-0033-1333567
- [48] Winthrop KL, McNelly E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features an emerging public health disease. American Journal of Respiratory and Critical Care Medicine 2010;**182**:977-982
- [49] Winthrop KL, Varley CD, Ory J, Cassidy PM, Hedberg K. Pulmonary disease associated with nontuberculous mycobacteria, Oregon, USA. Emerging Infectious Diseases. 2011;**9**:1760-1761. DOI: 10.3201/eid1709.101929
- [50] Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, Fujita K, Takakura S, Niimi A, Iinuma Y, Ichiyama S, Togashi K, Mishima M. Environmental risk factors for pulmonary *Mycobacterium avium-intracellulare* complex disease. Chest. 2011;**140**(3):723-729
- [51] Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerging Infectious Diseases. 2016;**22**:1116-1117
- [52] Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerging Infectious Diseases. 2010;**16**:1576-1583. DOI: 10.3201/eid1610.091201
- [53] Lee SK, Lee EJ, Kim SK, Chang J, Jeong SH, Kang YA. Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scandinavian Journal of Infectious Diseases. 2012;**44**:733-738

- [54] Yoon HJ, Choi HY, Ki M. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea. *BMC Infectious Diseases*. 2017;**17**:432. DOI: 10.1186/s12879-017-2532-4
- [55] Prevots DR, Marras TK. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: A Review. *Clinics in Chest Medicine*. 2015;**36**:13-34. DOI: 10.1016/j.ccm.2014.10.002
- [56] Ringshausen FC, Wagner D, de Roux A, Diel R, Hohmann D, Hickstein L, Welte T, Rademacher J. Prevalence of Nontuberculous mycobacterial pulmonary disease, Germany, 2009-2014. *Emerging Infectious Diseases*. 2016;**22**:1102-1105. DOI: <http://dx.doi.org/10.3201/eid2206.151642>
- [57] Chanda-Kapata P, Kapata N, Klinkenberg E, Mulenga L, Tembo M, Katemangwe P, Sunkutu V, Mwaba P, Grobusch M P. Non-tuberculous Mycobacteria (NTM) in Zambia: Prevalence, clinical, radiological and microbiological characteristics. *BMC Infectious Diseases*. 2015;**15**:500. DOI 10.1186/s12879-015-1264-6
- [58] Kim C, Park SH, Oh SY, Kim S-S, Jo K-W, Shim TS, Kim MY. Comparison of chest CT findings in nontuberculous mycobacterial diseases vs. *Mycobacterium tuberculosis* lung disease in HIV-negative patients with cavities. *PLoS One*. 2017;**12**:e0174240
- [59] Al-Ghafli H, Al-Hajoj S. Nontuberculous mycobacteria in Saudi Arabia and gulf countries: A review. *Canadian Respiratory Journal*. 2017. DOI: <https://doi.org/10.1155/2017/5035932>
- [60] Velayati AA, Rahideh S, Nezhad ZD, Farnia P, Mirsaeidi M. Nontuberculous mycobacteria in Middle East: Current situation and future challenges. *International Journal of Mycobacteriology*. 2015;**4**:7-17
- [61] Varghese B, Enani M, Shoukri M, AlThawadi S, AlJohani S, Al-Hajoj S. Emergence of rare species of nontuberculous mycobacteria as potential pathogens in Saudi Arabian clinical setting. *PLOS Neglected Tropical Diseases*. 2017. DOI: 10.1371/journal.pntd.0005288
- [62] Sookan L, Coovadia YM. A laboratory-based study to identify and speciate non-tuberculous mycobacteria isolated from specimens submitted to a central tuberculosis laboratory from throughout KwaZulu-Natal Province, South Africa. *South African Medical Journal* 2014;**10**:766-788. DOI: 10.7196/SAMJ.8017
- [63] Panagiotou M, Papaioannou AI, Kostikas K, Paraskeua M, Velentza E, Kanellopoulou M, Filaditaki V, Karagiannidis N. The epidemiology of pulmonary nontuberculous mycobacteria: Data from a General Hospital in Athens, Greece, 2007-2013. *Pulmonary Medicine*. 2014. DOI: <http://dx.doi.org/10.1155/2014/894976>
- [64] Jing H, Wang H, Wang Y, Deng Y, Li X, Liu Z, Graviss EA, Ma X. Prevalence of non-tuberculous mycobacteria infection, China, 2004-2009. *Emerging Infectious Diseases*. 2012;**18**:527-528. DOI: <http://dx.doi.org/10.3201/eid1803.110175>
- [65] Duan H, Han X, Wang Q, Wang J, Wang J, Chu N, Huang H. Clinical significance of non-tuberculous mycobacteria isolated from respiratory specimens in a Chinese tuberculosis tertiary care center. *Scientific Reports*. 2016. DOI: 10.1038/srep36299

- [66] Zhang W, Liu W, Fang G, Ma J, Huang C, Zhang D. Pathogenicity and susceptibility profile of nontuberculous mycobacteria from 16,578 suspected pulmonary tuberculosis patients. *International Journal of Clinical and Experimental Medicine*. 2017;**10**:242-254
- [67] Desikan P, Tiwari K, Panwalkar N, Khaliq S, Chourey M, Varathe R, Mirza SB, Sharma A, Anand S, Pandey M. Public health relevance of non-tuberculous mycobacteria among AFB positive sputa. *GERMS Journal*. 2017;**7**
- [68] Umrao J, Singh D, Zia A, Saxena S, Sarsaiya S, Singh S, Khatoon J, Dhole TN. Prevalence and species spectrum of both pulmonary and extrapulmonary nontuberculous mycobacteria isolates at a tertiary care center. *International Journal of Mycobacteriology*. 2016;**5**:288-293. DOI: <https://doi.org/10.1016/j.ijmyco.2016.06.008>Get rights and content
- [69] Kankya C, Muwonge A, Djønne B, Munyeme M, Opuda-Asibo J, Skjerve E, Oloya J, Edvardsen V, Johansen TB. Isolation of non-tuberculous mycobacteria from pastoral ecosystems of Uganda: Public health significance. *BMC Public Health*. 2011;**11**:320. DOI: <http://www.biomedcentral.com/1471-2458/11/320>
- [70] Sood A, Sreedhar R, Kulkarni P, Nawoor AR. Hypersensitivity pneumonitis-like granulomatous lung disease with nontuberculous mycobacteria from exposure to hot water aerosols. *Environmental Health Perspectives*. 2007;**115**:262-266
- [71] Heynekamp T, Sood A, Busby H. Hot tub lung from *Mycobacterium asiaticum*. *Chest*. 2011;**140**(4th Meeting Abstracts):156A. DOI: 10.1378/chest.1118282
- [72] Utsugi H, Usui Y, Nishihara F, Kanazawa M, Nagata M. *Mycobacterium gordonae*-induced humidifier lung. *BMC Pulmonary Medicine*. 2015;**15**:108. DOI 10.1186/s12890-015-0107-y
- [73] McGrath EE, Blades Z, McCabe J, Jarry H, Anderson PB. Nontuberculous mycobacteria and the lung: From suspicion to treatment. *Lung*. 2010;**188**:269-282. DOI: 10.1007/s00408-010-9240-9 (Epub Apr 9, 2010)
- [74] Yoo SH, Kim SR, Choi JY, Choi JW, Ko YM, Jang SH, Park JK, Sung YG, Park YJ, Oh SY, Bahk SY, Lee JH, Kim MS. Multiple cavitary pulmonary nodules caused by *Mycobacterium intracellulare*. *Korean Journal of Family Medicine*. 2016;**37**:248-252
- [75] Im SA, Park HJ, Park SH, Chun HJ, Jung WS, Kim SH. Consolidations in nodular bronchiectatic *Mycobacterium avium* complex lung disease: *Mycobacterium avium* complex or other infection? *Yonsei Medical Journal*. 2010;**51**:546-551
- [76] Koh WJ, Kwon OJ. Bronchiectasis and non-tuberculous mycobacterial pulmonary infection. *Thorax*. 2006;**61**:458
- [77] Lim J, Lyu J, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Lee H, Shim TS. Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules. *The International Journal of Tuberculosis and Lung Disease*. 2010;**14**:1635-1640
- [78] Kwon YS, Koh W-J, Chung MP, Kwon OJ, Lee NY, Cho EY, Han J, Kim TS, Lee KS, Kim B-T. Solitary pulmonary nodule due to *Mycobacterium intracellulare*: The first case in Korea. *Yonsei Medical Journal*. 2007;**48**:127-130. DOI: 10.3349/ymj.2007.48.1.127

- [79] Bermudez LE, Martin WU, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of *Mycobacterium avium*. *Infection and Immunity*. 1995;**63**:4099-4104
- [80] Holland SM. Host defense against nontuberculous mycobacterial infections. *Seminars in Respiratory Infections*. 1996;**11**:217-230
- [81] Bai X, Ovrutsky AR, Kartalija M, Chmura K, Kamali A, Honda JR, Oberley-Deegan RE, Dinarello CA, Crapo JD, Chang L-Y, Chan ED. IL-32 expression in the airway epithelial cells of patients with *Mycobacterium avium* complex lung disease. *International Immunology*. 2011;**11**:679-691
- [82] Jouanguy E, Döffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. *Current Opinion in Immunology*. 1999;**11**:346-351
- [83] Han J-Y, Rosenzweig SD, Church JA, Holland SM, Ross LA. Variable presentation of disseminated nontuberculous mycobacterial infections in a family with an interferon-g receptor mutation. *Clinical Infectious Diseases*. 2004;**39**:868-870
- [84] Hussain T, Shah SZA, Zhao D, Sreevatsan S, Zhou X. The role of IL-10 in *Mycobacterium avium* subsp. paratuberculosis infection. *Cell Communication and Signaling*. 2016;**14**:29. DOI: 10.1186/s12964-016-0152-z
- [85] Lake MA, Ambrose LR, Lipman MCI, Lowe DM. Why me, why now? Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. *BMC Medicine*. 2016;**14**:54. DOI: <https://doi.org/10.1186/s12916-016-0606-6>
- [86] Henkle E, Winthrop K. Nontuberculous mycobacteria infections in immunosuppressed hosts. *Clinics in Chest Medicine*. 2015;**36**:91-99. DOI: 10.1016/j.ccm.2014.11.002
- [87] Zaidi S, Elidemir O, Heinle JS, McKenzie ED, Schecter MG, Kaplan SL, et al. *Mycobacterium abscessus* in cystic fibrosis lung transplant recipients: Report of 2 cases and risk for recurrence. *Transplant Infectious Disease*. 2009;**11**:243-248
- [88] Lai CC, Tan CK, Cheng A, Chung KP, Chen CY, Liao CH, Huang YT, Hsueh PR. Nontuberculous mycobacterial infections in cancer patients in a medical center in Taiwan, 2005-2008. *Diagnostic Microbiology and Infectious Disease*. 2012;**72**:161-165
- [89] Meier E, Pennington K, de Moraes AG, Escalante P. Characteristics of *Mycobacterium avium* complex (MAC) pulmonary disease in previously treated lung cancer patients. *Respiratory Medicine Case Reports*. 2017;**22**:70-73
- [90] Tsuji T, Tsuyuguchi K, Tachibana K, Kimura Y, Kobayashi T, Minomo S, Atagi S, Matsumura A, Hayashi S, Suzuki K. Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases. *The Japanese Respiratory Society*. 2017; **55**:45-50. DOI: <http://dx.doi.org/10.1016/j.resinv.2016.08.002>
- [91] Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. *The European Respiratory Journal*. 2008;**31**:1322-1333. DOI: 10.1183/09031936.00140007

- [92] Liao T-L, Lin C-F, Chen Y-M, Liu H-J, Chen D-Y. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: A case-control study in a TB endemic area. *Scientific Reports*. 2016. DOI: 10.1038/srep29443
- [93] Philley J, Guthrie C, Whitehead S, Cook A, Benwill J, Brown-Elliott B, Obayangban S, Wyatt L, Flores R, Ramirez P, McClendon R, Drake T, Wilhite V, Murphy A, Wallace R, Griffith D. A possible association between breast cancer, bronchiectasis and nontuberculous mycobacterial (NTM) lung disease. *European Respiratory Journal*. 2014;**44**:2532
- [94] Riello FN, Brígido RTS, Araujo S, Moreira TA, Goulart LR, Goulart IMB. Diagnosis of mycobacterial infections based on acid-fast bacilli test and bacterial growth time and implications on treatment and disease outcome. *BMC Infectious Diseases*. 2016;**16**:142
- [95] Buijtel PC, van der Sande MA, Parkinson S, Verbrugh HA, Petit PL, van Soolingen D. Isolation of non-tuberculous mycobacteria at three rural settings in Zambia: A pilot study. *Clinical Microbiology and Infection*. 2010;**16**:1142-1148. DOI: 10.1111/j.1469-0691.2009.03072.x (Epub Oct 14, 2009)
- [96] dos Santos RP, Scheid KL, Willers DMC, Goldani LZ. Comparative radiological features of disseminated disease due to *Mycobacterium tuberculosis* vs non-tuberculosis mycobacteria among AIDS patients in Brazil. *BMC Infectious Diseases*. 2008;**8**:24. DOI: 10.1186/1471-2334-8-24
- [97] Godet C, Elsendoorn A, Roblot F. Benefit of CT scanning for assessing pulmonary disease in the immunodepressed patient. *Diagnostic and Interventional Imaging*. 2012;**93**:425-430
- [98] Yuan MK, Chang CY, Tsai PH, Lee YM, Huang JW, Chang SC. Comparative chest computed tomography findings of non-tuberculous mycobacterial lung diseases and pulmonary tuberculosis in patients with acid fast bacilli smear-positive sputum. *BMC Pulmonary Medicine*. 2014;**14**:65
- [99] Chu HQ, Zhao BLL, Huang DD, Zhang ZM, Xu JF, Zhang JB, Gui T, Xu LY, Sun XW. Chest imaging comparison between non-tuberculous and tuberculosis mycobacteria in sputum acid fast bacilli smear-positive patients. *European Review for Medical and Pharmacological Sciences*. 2015;**19**:2429-2439
- [100] Lee Y, Song JW, Chae J, Lee HJ, Lee CW, Do KH, Seo JB, Kim MY, Lee JS, Song KS, Shim TS. CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: A case-controlled comparison with immunocompetent patients. *The British Journal of Radiology*. 2013;**86**:1-11. DOI: 10.1259/bjr.20120209
- [101] Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: Clinicians' perspectives. *Tuberculosis and Respiratory Diseases*. 2016;**79**:74-84
- [102] Keskin S, Sakarya ME, Keskin Z. CT findings of *Mycobacterium avium intracellulare* infections in the lung. *European Journal of General Medicine*. 2014;**11**:296-298. DOI: 10.15197/sabad.1.11.92

- [103] Gommans EPAT, Even P , Linssen CFM, van Dessel H, van Haren E, de Vries GJ, Dingemans AMC , Kotz D, Rohde GGU. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: A retrospective cohort study. *Respiratory Medicine* 2015;**109**:137-145
- [104] Ogbaini-Emovon E. Current trends in the laboratory diagnosis of tuberculosis. *Benin Journal of Postgraduate Medicine*. 2009;**11**:79-90
- [105] Wright PW, Richard J. Wallace JR, Wright NW, Brown BA, Griffith DE. Sensitivity of fluorochrome microscopy for detection of *Mycobacterium tuberculosis* versus nontuberculous mycobacteria. *Journal of Clinical Microbiology*. 1998;**36**:1046-1049
- [106] Ley S, Carter R, Millan K, Phuanukoonnon S, Pandey S, Coulter C, Siba P, Beckab H-P. Non-tuberculous mycobacteria: Baseline data from three sites in Papua New Guinea, 2010-2012. *Western Pacific Surveillance and Response Journal*. 2015;**6**:24-29. DOI: 10.5365/wpsar.2015.6.2.004
- [107] De Kantor IN, Kim SJ, Frieden T, Laszlo A, Luelmo F, Norval P-Y, Rieder H, Valenzuela P, Weyer K. *Laboratory Services in Tuberculosis Control: Culture Part III*. Geneva, Switzerland: World Health Organization; 1998
- [108] Tortoli E, Cichero P, Piersimoni C, Simonetti MT, Gesu G, Nista D. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: Multicenter study. *Journal of Clinical Microbiology*. 1999;**37**:3578-3582
- [109] Kargupta R, Puttaswamy S, Lee AJ, Butler TE, Li Z, Chakraborty S, Sengupta S. Rapid culture-based detection of living mycobacteria using microchannel electrical impedance spectroscopy (m-EIS). *Biological Research*. 2017;**50**:21. DOI: 10.1186/s40659-017-0126-7
- [110] Samra Z, KaufmannL, Zeharia A, Ashkenazi S, Amir J, Bahar J, Reischl U, Naumann L. Optimal detection and identification of *Mycobacterium haemophilum* in specimens from pediatric patients with cervical lymphadenopathy. *Urnal of Clinical Microbiology*. 1999;**37**:32-834
- [111] Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: Improved reverse hybridization multiple DNA probe assay for mycobacterial identification. *Journal of Clinical Microbiology*. 2003;**41**:4418-4420
- [112] Senanayake NP, Eriyagama NB, Thevanesam V. Identification of non-tuberculous-mycobacteria isolated from patients at teaching hospitals, Kandy and Peradeniya Sri Lankan *Journal of Infectious Diseases*. 2016;**6**:33-42. DOI: <http://dx.doi.org/10.4038/sljid.v6i1.810>
- [113] Park JS, Choi JI, Lim JH, Ahn JJ, Jegal Y, Seo KW, Ra SW, Jeon JB, Lee SH, Kim SR, Jeong J. The combination of real-time PCR and HPLC for the identification of non-tuberculous mycobacteria. *Annals of Laboratory Medicine*. 2013;**33**:349-352
- [114] Kim JU, Cha CH, An HK. Multiplex real-time PCR assay and melting curve analysis for identifying *Mycobacterium tuberculosis* complex and nontuberculous mycobacteria. *Journal of Clinical Microbiology*. 2011;**50**:483-487. DOI: 10.1128/JCM.06155-11

- [115] Bainomugisa A, Wampande E, Muchwa C, Akol J, Mubiri P, Ssenyungule H, Matovu E, Ogwang S, Joloba M. Use of real time polymerase chain reaction for detection of *M. tuberculosis*, *M. avium* and *M. kansasii* from clinical specimens. BMC Infectious Diseases. 2015;**15**:181. DOI: 10.1186/s12879-015-0921-0
- [116] Omar SV, Roth A, Ismail NA, Erasmus L, Ehlers M, Kock M, Paulse N, Said HM, Hoosen AA, Reisch U. Analytical performance of the Roche Light Cycler H *Mycobacterium* detection kit for the diagnosis of clinically important mycobacterial species. PLoS One. 2011;**6**:1-6. DOI: 10.1371/journal.pone.0024789
- [117] Gitti Z, Neonakis I, Fanti G, Kontos F, Maraki S, Tselentis Y. Use of the GenoType *Mycobacterium* CM and AS assays to analyze 76 nontuberculous mycobacterial isolates from Greece. Journal of Clinical Microbiology. 2006;**44**:2244-2246
- [118] Singh AK, Maurya AK, Umrao J, Kant S, Kushwaha RAS, Nag VL, Dhole TN. Role of GenoType® *Mycobacterium* common mycobacteria/additional species assay for rapid differentiation between mycobacterium tuberculosis complex and different species of non-Tuberculous mycobacteria. Journal of Laboratory Physicians. 2013;**5**:83-89. DOI: 10.4103/0974-2727.119847
- [119] Lee AS, Jelfs P, Sintchenko V, Gilbert GL. Identification of non-tuberculous mycobacteria: Utility of the GenoType *Mycobacterium* CM/AS assay compared with HPLC and 16S rRNA gene sequencing. Journal of Medical Microbiology. 2009;**58**:900-904. DOI: 10.1099/jmm.0.007484-0
- [120] Maurya AK, NagVL, Kant S, Sharma A, Gadepalli RS, Kushwaha RAS. Recent methods for diagnosis of nontuberculous mycobacteria infections: Relevance in clinical practice. Biomedical and Biotechnology Research Journal. 2017;**1**:14-18
- [121] Suffys PN, Da SA, De Oliveira M, Campos CED, Barreto AMW, Portaels F, Rigouts L, Wouters G, Jannes G, Van Reybroeck G, Mijs W, Vanderborght B. Rapid identification of mycobacteria to the species level using INNO-LiPA mycobacteria, a reverse hybridization assay. Journal of Clinical Microbiology. 2001;**39**:4477-4482. DOI: 10.1128/JCM.39.12.4477-4482.2001
- [122] García-Agudo L, Jesús I, Rodríguez-Iglesias M, García-Martos P. Evaluation of Inno-Lipa mycobacteria V2 assay for identification of rapidly growing mycobacteria. Brazilian Journal of Microbiology. 2011;**42**:1220-1226
- [123] Therese KL, Bartell J, Deepa P, Mangaiyarkarasi S, Ward D, Dajcs J, Madhavan HN, Stroman D. DNA sequencing by Microseq kit targeting 16S rRNA gene for species level identification of mycobacteria. The Indian Journal of Medical Research. 2009;**129**:176-181
- [124] de Zwaan R, van Ingen J, van Soolingena D. Utility of *rpoB* gene sequencing for identification of nontuberculous mycobacteria in the Netherlands. Journal of Clinical Microbiology. 2014;**52**:2544-2551
- [125] Adekambi T, Berger P, Raoult D, Drancourt M. *rpoB* gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of *Mycobacterium bolletii*

- sp. nov., *Mycobacterium phocaicum* sp. nov. and *Mycobacterium aubagnense* sp. nov. International Journal of Systematic and Evolutionary Microbiology. 2006;**56**:133-143. DOI: 10.1099/ijs.0.63969-0
- [126] Salah IB, Adekambi T, Raoult D, Drancourt M. rpoB sequence-based identification of *Mycobacterium avium* Complex species. Microbiology. 2008;**154**:3715-3723. DOI: 10.1099/mic.0.2008/020164-0
- [127] Zelazny AM, Calhoun LB, Li L, Shea YR, Fischer SH. Identification of *Mycobacterium* species by secA1 sequences. Journal of Clinical Microbiology. 2005;**43**:1051-1058
- [128] Kim H, Kim SH, Shim TS, Kim M, Bai GH, Park YG, Lee SH, Chae GT, Cha CY, Kook YH, Kim BJ. Differentiation of *Mycobacterium* species by analysis of the heat-shock protein 65 gene (hsp65). International Journal of Systematic and Evolutionary Microbiology. 2005;**55**:1649-1656. DOI: 10.1099/ijs.0.63553-0
- [129] Fukushima M, Kakinuma K, Hayashi H, Nagai H, Ito K, Kawaguchi R. Detection and identification of *Mycobacterium* species isolates by DNA microarray. Journal of Clinical Microbiology. 2003;**41**:2605-2615. DOI: 10.1128/JCM.41.6.2605-2615.2003
- [130] Wildner LM, Bazzo ML, Liedke SC, Nogueira CL, Segat G, Senna SG, Schlindwein AD, de Oliveira JG, Rovaris DB, Bonjardim CA, Kroon EG, Ferreira PCP. Mycobacteria mobility shift assay: A method for the rapid identification of *Mycobacterium tuberculosis* and nontuberculous mycobacteria. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro. 2014;**109**:356-361
- [131] Zhu L, Jiang G, Wang S, Wang C, Li Q, Yu H, Zhou Y, Zhao B, Huang H, Xing W, Mitchelson K, Cheng J, Zhao Y, Guo Y. Biochip system for rapid and accurate identification of mycobacterial species from isolates and sputum. Journal of Clinical Microbiology. 2010;**48**:3654-3660. DOI: 10.1128/JCM.00158-10
- [132] Wang H, Yue J, Han M, Yang J, Zhao Y. Rapid method For identification of six common species of mycobacteria based on multiplex SNP analysis. Journal of clinical Microbiology. 2010;**48**:47-250. DOI: 10.1128/JCM.01084-09
- [133] Woods GL, Barbara A, Patricia S, Edward P, Geraldine S, Grace L, Pfyffer GE, Ridderhof GC, Siddigi SH, Wallace RJ, Warrn NG, Witebsky FG. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard. CLSI Document M24-A2. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011
- [134] Renvoise A, Bernard C, Veziris N, Galati E, Jarlier V, Roberta J. Significant difference in drug susceptibility distribution between *Mycobacterium avium* and *Mycobacterium intracellulare*. Journal of Clinical Microbiology. 2014;**52**:4439-4440
- [135] Brown-Elliott BA, Richard JW. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clinical Microbiology Reviews. 2002;**15**:716-746. DOI: 10.1128/CMR.15.4.716-746.2002
- [136] Li G, Lian L, Wan L, Zhang J, Zhao X, et al. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue Assay. PLoS One. 2013;**8**:e84065. DOI: 10.1371/journal.pone.0084065

- [137] Sankar MM, Gopinath K, Singla R, Singh S. In-vitro antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay. *Annals of Clinical Microbiology and Antimicrobials*. 2008;**7**:1-9. DOI: 10.1186/1476-0711-7-15
- [138] Haworth CS, Floto RA, Banks J, Capstick T, Fisher A, Gorsuch T, Laurenson I, Leitch A, Loebinger M, Milburn H, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R. British Thoracic Society Guidelines for the Diagnosis and Management of Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD). London: British Thoracic Society; 2017. Available form: <https://www.brit-thoracic.org.uk/document-library/clinical-information/non-tuberculosis-mycobacteria/ntm-guideline/bts-guidelines-for-the-diagnosis-and-management-of-ntm-pd/>
- [139] Morimoto K, Namkoong H, Hasegawa N, Nakagawa T, Morino E, Shiraishi Y, Ogawa K, Izumi K, Takasaki J, Yoshiyama T, Hoshino Y, Matsuda S, Hayashi Y, Sasaki Y, Ishii M, Kurashima A, Nishimura T, Betsuyaku T, Goto H. Macrolide-resistant *Mycobacterium avium* complex lung disease: Analysis of 102 consecutive cases. *AnnalsATS Issues*. 2016;**13**. DOI: <https://doi.org/10.1513/AnnalsATS.201604-246OC>
- [140] Moon SM, Park HY, Kim S-Y, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Koh WJ. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant *Mycobacterium avium* Complex lung disease. *Antimicrobial Agents and Chemotherapy*. 2016;**60**:6758-6765. DOI: 10.1128/AAC.01240-16
- [141] Koh WJ, Hong G, Kim SY, Jeong BH, Park HY, Jeon K, Kwon OJ, Lee SH, Kim CK, Shinc SJ. Treatment of refractory *Mycobacterium avium* complex lung disease with a moxifloxacin- containing regimen. *Antimicrobial Agents and Chemotherapy*. 2013;**57**:2281-2285
- [142] Kadota T, Matsui H, Hirose T, Suzuki J, Saito M, Akaba T, Kobayashi K, Akashi S, Kawashima M, Tamura A, Nagai H, Akagawa S, Kobayashi N, Ohta K. Analysis of drug treatment outcome in clarithromycin-resistant *Mycobacterium Avium* complex lung disease. *BMC Infectious Diseases*. 2016;**16**:31. DOI: 10.1186/s12879-016-1384-7
- [143] Kang H K, Park HY, Kim D, Jeong BH, Jeon K, Cho JH, Kim HK, Choi YS, Kim J, Koh WJ. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. *BMC Infectious Diseases*. 2015;**15**:76. DOI: 10.1186/s12879-015-0823-1
- [144] Shiraishi Y, Katsuragi N, Kita H, Hyogotani A, Saito MH, Shimoda K. Adjuvant surgical treatment of nontuberculous mycobacterial lung disease. *The Annals of Thoracic Surgery*. 2013;**96**:287-291. DOI: 10.1016/j.athoracsur. 2013.03.008 (Epub Apr 22, 2013)
- [145] Karakousis PC, Moore RD, Chaisson RE. *Mycobacterium avium* Complex in patients with HIV infection in the era of highly active antiretroviral therapy. *The Lancet Infectious Diseases*. 2004;**4**:557-565